ArticleBMC neurology2025
Prevalence of epsilon toxin-producing Clostridium perfringens isolates among patients with multiple sclerosis and neuromyelitis optica spectrum disorder in Iran.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundClostridium perfringens epsilon toxin (ETX) is a potent neurotoxin that crosses the blood-brain barrier (BBB), and has been suggested to be involved in demyelinating CNS disorders. Here, we investigated the prevalence of C. perfringens and anti-ETX immunoglobulin G (IgG) and immunoglobulin M (IgM) antibody levels in stool and sera of patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) compared to healthy controls.
methodsBetween September 2019 and June 2020, 43 stool and 43 sera specimens were collected from MS (n = 33) and NMOSD (n = 10) patients, and 49 samples from healthy subjects. Stool samples were cultured for the presence of C. perfringens and PCR was used to detect etx-encoding gene. The level of serum IgG and IgM against ETX was examined using competitive ELISA. The predictive value of sex, age, ETX IgG and IgM levels, and C. perfringens was assessed using multivariable prediction models, with all models trained on the full set of variables. Independent contributions were evaluated separately using logistic regression (LR) analysis.
resultsTotally, 11 C. perfringens were isolated from MS (n = 4), NMOSD (n = 2), and healthy (n = 5) subjects. The etx gene was detected in 1/4 (25%) isolates from MS and 2/2 (100%) from NMOSD patients, while none of the isolates from healthy subjects carried the gene. The analysis of serum IgG and IgM level against ETX showed no significant difference between patients and healthy subjects. Among the prediction models used, LR and Naïve Bayes (NB), trained on all predictor variables, exhibited the highest statistical accuracy for MS diagnosis, with AUC = 0.71 and AUC = 0.93, respectively. Among individual parameters, sex (AUC = 0.63) and IgG level (AUC = 0.57) were the most reliable predictors. The nomogram prediction demonstrated that the probability of patients' risk of developing MS and NMOSD can be predicted using these predictors.
conclusionsOur findings indicate a potential association between ETX-producing C. perfringens strains and MS/NMOSD diseases, as its presence was detected in a subset of patient samples. However, no significant differences in anti-ETX antibody levels were observed between control and patients. Our prediction models highlighted key demographic and serological factors that may contribute to MS diagnosis. These results highlight the need for further research to meticulously decipher the biological interplay of C. perfringens and its ETX toxin with the development of MS and NMOSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.